ARYNTA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Arynta, and what generic alternatives are available?
Arynta is a drug marketed by Azurity and is included in one NDA. There are three patents protecting this drug.
This drug has seventeen patent family members in sixteen countries.
The generic ingredient in ARYNTA is lisdexamfetamine dimesylate. Twenty-one suppliers are listed for this compound. Additional details are available on the lisdexamfetamine dimesylate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Arynta
A generic version of ARYNTA was approved as lisdexamfetamine dimesylate by ACTAVIS ELIZABETH on August 25th, 2023.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ARYNTA?
- What are the global sales for ARYNTA?
- What is Average Wholesale Price for ARYNTA?
Summary for ARYNTA
| International Patents: | 17 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Patent Applications: | 341 |
| What excipients (inactive ingredients) are in ARYNTA? | ARYNTA excipients list |
| DailyMed Link: | ARYNTA at DailyMed |
Pharmacology for ARYNTA
| Drug Class | Central Nervous System Stimulant |
| Physiological Effect | Central Nervous System Stimulation |
US Patents and Regulatory Information for ARYNTA
ARYNTA is protected by three US patents.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Azurity | ARYNTA | lisdexamfetamine dimesylate | SOLUTION;ORAL | 219847-001 | Jun 16, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Azurity | ARYNTA | lisdexamfetamine dimesylate | SOLUTION;ORAL | 219847-001 | Jun 16, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Azurity | ARYNTA | lisdexamfetamine dimesylate | SOLUTION;ORAL | 219847-001 | Jun 16, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ARYNTA
See the table below for patents covering ARYNTA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2020416052 | Oral solutions comprising lisdexamfetamine salts | ⤷ Start Trial |
| Brazil | 112022012986 | SOLUÇÕES ORAIS COMPREENDENDO SAIS DE LISDEXAMFETAMINA | ⤷ Start Trial |
| Canada | 3165248 | SOLUTIONS ORALES COMPRENANT DES SELS DE LISDEXAMFETAMINE (ORAL SOLUTIONS COMPRISING LISDEXAMFETAMINE SALTS) | ⤷ Start Trial |
| Chile | 2022001792 | Soluciones orales que comprenden sales de lisdexanfetamina | ⤷ Start Trial |
| Colombia | 2022010594 | Soluciones orales que comprenden sales de lisdexanfetamina | ⤷ Start Trial |
| Denmark | 3845215 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ARYNTA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1644019 | 122013000079 | Germany | ⤷ Start Trial | PRODUCT NAME: LISDEXAMFETAMINE ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DESSEN, WIE L-LYSIN-D-AMPHETAMIN-MESYLAT; REGISTRATION NO/DATE: 86155.00.00 86156.00.00 86157.00.00 20130318; FIRST REGISTRATION: UK PL 08081/0050-2 20130201 |
| 1644019 | 2013/038 | Ireland | ⤷ Start Trial | PRODUCT NAME: LISDEXAMFETAMINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY A MESYLATE SALT; NAT REGISTRATION NO/DATE: PA0689/006/001 PA0689/006/002 |
| 1644019 | SPC/GB13/052 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: LISDEXAMFETAMINE OPTIONALLY IN THE FORM OF A MESYLATE OR HYDROCHLORIDE SALT THEREOF; REGISTERED: UK PL08081/0050-2 20130201; UK PL08081/0062-4 20130201 |
| 1644019 | 301019 | Netherlands | ⤷ Start Trial | PRODUCT NAME: LISDEXAMFETAMINE, DESGEWENST IN DE VORM VAN EEN MESYLAAT- OF HYDROCHLORIDEZOUT DAARVAN; NATIONAL REGISTRATION NO/DATE: RVG 124498 20190528; FIRST REGISTRATION: GB PL 08081/0050-52 20130201 |
| 1644019 | LUC00189 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: LISDEXAMFETAMINE, OPTIONALLY IN THE FORM OF A MESYLATE OR HYDROCHLORIDE SALT THEREOF; AUTHORISATION NUMBER AND DATE: PL08081/0050-52 20200901 |
| 1644019 | 2020C/543 | Belgium | ⤷ Start Trial | PRODUCT NAME: LISDEXAMFETAMINE, OPTIONEEL IN DE VORM VAN EEN MESYLAAT- OF HYDROCHLORIDE-ZOUT HIERVAN; AUTHORISATION NUMBER AND DATE: BE562026, BE562035, BE562044, BE562053, BE562062, BE562071 20200520 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch